Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

Athol U Wells; Simon Walsh; Florence Le Maulf; Luca Richeldi; Yoshikazu Inoue; William Mezzanotte; Kevin K Brown; Kevin R Flaherty; Anand Devaraj; Rozsa Schlenker-Herceg; Emmanuelle Clerisme-Beaty; Hendrik Schmidt; Vincent Cottin; Harold R Collard

首页> 外文期刊>BMJ Open Respiratory Research >Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

【24h】

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

机译：PF-ILD试验的设计：Nintedanib在进行性纤维化间质性肺疾病患者中的双盲，随机，安慰剂对照的III期临床试验

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Abstract 600 patients aged ?￠??￥18 years will be randomised in a 1:1 ratio to nintedanib or placebo. Patients with diagnosis of IPF will be excluded. The study population will be enriched with two-thirds having a usual interstitial pneumonia-like pattern on

机译：摘要将600名18岁以下的患者按1：1比例随机分配至nintedanib或安慰剂。诊断为IPF的患者将被排除在外。研究人群中将有三分之二的人患有典型的间质性肺炎样疾病

著录项

来源
《BMJ Open Respiratory Research》 |2017年第1期|共页
作者
Athol U Wells; Simon Walsh; Florence Le Maulf; Luca Richeldi; Yoshikazu Inoue; William Mezzanotte; Kevin K Brown; Kevin R Flaherty; Anand Devaraj; Rozsa Schlenker-Herceg; Emmanuelle Clerisme-Beaty; Hendrik Schmidt; Vincent Cottin; Harold R Collard;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类临床医学;
关键词

相似文献

外文文献
中文文献
专利

1. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial [J] . The lancet. Respiratory medicine. . 2020,第5期

机译：Nintedanib患者患有初步抗体性肺病疾病 - 亚组通过内联肺病诊断分析：随机，双盲，安慰剂，并联群试验
2. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial [J] . Maher Toby M., Corte Tamera J., Fischer Aryeh, The lancet. Respiratory medicine. . 2020,第2期

机译：Pirfenidone患者患者无分类渐进式间质性肺病：双盲，随机，安慰剂控制，第2期试验
3. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer [J] . Novello Silvia, Kaiser Rolf, Mellemgaard Anders, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2015,第3期

机译：分析烟雾肺1试验的患者报告的结果：一种随机，双盲，安慰剂控制，第三阶段九丁酰胺患者在高小细胞肺癌患者中的研究III研究
4. EFFECT OF TARGETED PULSED ELECTROMAGNETIC FIELD THERAPY ON CANINE POST-OPERATIVE HEMILAMINECTOMY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL [C] . ACVS Veterinary Symposium . 2018

机译：靶向脉冲电磁场治疗对犬术后血栓切除术的影响：双盲，随机，安慰剂对照临床试验
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Design of the PF-ILD trial: a double-blind randomised placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease [O] . Kevin R Flaherty, Kevin K Brown, Athol U Wells, 2017

机译：PF-ILD试验的设计：Nintedanib在进行性纤维化间质性肺疾病患者中的双盲随机安慰剂对照的III期临床试验
7. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. [O] . Flaherty, KR, Brown, KK, Wells, AU, 2017

机译：pF-ILD试验的设计：对进行性纤维化间质性肺病患者进行的双盲，随机，安慰剂对照III期试验。

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

摘要

著录项

相似文献

相关主题

期刊订阅